Paradox Immunotherapeutics is a pharmaceutical company developing immunotherapies for diseases caused by misfolding of proteins (defects in protein structure). The company’s lead product, LX-96, is an antibody to treat organ failure caused by Amyloid light-chain (AL) amyloidosis—a disease caused by protein misfolding, where the defective proteins clog organs, particularly the heart and kidneys. LX-96 specifically targets the diseased proteins that are deposited in organs, while leaving the healthy forms of these proteins untouched.